<DOC>
	<DOCNO>NCT02315053</DOCNO>
	<brief_summary>A prospective observational study determine prognostic value time 50 % reduction metabolic activity ( T50 ) CCRT NSCLC treatment outcome ( PFS ) .</brief_summary>
	<brief_title>PET Response During Chemoradiation Lung Cancer</brief_title>
	<detailed_description>This single‐centre observational study . Patients proven locally advanced NSCLC treat concurrent chemoradiotherapy accord standard clinical protocol NKI‐AVL . During treatment , biological behaviour tumour monitor serial quantitative FDG ( fluorodeoxyglucose ) PET/CT scan . From image , time treatment 50 % reduction FDG uptake relative day 1 reach ( T50 ) derive . The T50 progression‐free survive patient compare relapse deceased patient , order find value predict early treatment failure . An additional FDG PET/CT scan day regular follow CT scan make , two month treatment , baseline treatment follow .</detailed_description>
	<criteria>Cytologically histologically proven NSCLC T2‐4 N0‐3 M0 disease ( stage II III , inoperable ) Scheduled standard concurrent chemoradiation Primary tumour minimal diameter 3 cm Primary tumour SUVmax &gt; 5 routine diagnostic pre‐treatment FDG ( Fludeoxyglucose ) PET/CT WHO performance 0‐1 Written inform consent accord GCP ( Good Clinical Practice ) national regulation Age &lt; 18 year , incapacitated subject Pregnant lactate woman Diabetes mellitus require medication Participation dose escalation study Other neoplasms last 3 year , metastasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>CCRT</keyword>
	<keyword>FDG PET/CT</keyword>
</DOC>